Advertisement

PET/CT in Assessment of Sarcoidosis

  • Ashwini Kalshetty
  • Pradeep Thapa
  • Sandip Basu
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Sarcoidosis is a multi-systemic disease of unknown aetiology with a unique set of diagnostic and management related challenges. PET/CT has been studied extensively for assessing the sites of inflammatory activity and extent of disease. 18FDG PET/CT imaging is a non-invasive tool to assess disease activity, localize occult sites, increases the yield of biopsy, helps in optimizing treatment and detection of relapse. As FDG accumulation is non-specific to the disease process, PET CT can only serve to give complimentary information. With recent availability of many new PET tracers, it may be possible to individualize and optimize treatment; however, larger prospective trials are required to establish their utility. The role of newer technologies like PET/MR and newer tracers (eg. Somatostatin receptor agonists) are exploratory at this time point.

References

  1. 1.
    Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.Google Scholar
  2. 2.
    Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55:66–71.PubMedGoogle Scholar
  4. 4.
    Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.PubMedGoogle Scholar
  5. 5.
    Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–9.PubMedGoogle Scholar
  6. 6.
    Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDGPET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53:1543–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, Grutters JC. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36(7):1131–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Dalma VA, van hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285:E344–53.CrossRefGoogle Scholar
  10. 10.
    ten Bokum AM, Hofland LJ, de Jong G, et al. Immunohistochemical localization of somatostatin receptor in sst2A in sarcoid granuloma. Eur J Clin Investig. 1999;29:630–6.CrossRefGoogle Scholar
  11. 11.
    Soydal C, Kucuk O, Ozkan E, Kumbasar O, Kir M. Ga-68 DOTATATE accumulation in sarcoidosis. Int J Nucl Medi Res. 2015;2:1–4.CrossRefGoogle Scholar
  12. 12.
    Nobashi T, Nakamoto Y, Kubo T, Ishimori T, Handa T, Tanizawa K, Sano K, Mishima M, Togashi K. The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy. Ann Nucl Med. 2016;30(8):544–52.CrossRefPubMedGoogle Scholar
  13. 13.
    Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86.PubMedGoogle Scholar
  14. 14.
    Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med. 2010;31:409–18.CrossRefPubMedGoogle Scholar
  15. 15.
    Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Drent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol. 2003;13:2462–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol. 2000;174:1751–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Vöö S, Drent M. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2013;107(3):439–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, Hughes JM. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21(4):297–305.CrossRefPubMedGoogle Scholar
  20. 20.
    Keijsers RG, Verzijlbergen EJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, Grutters JC. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123–9.PubMedGoogle Scholar
  21. 21.
    Basu S, Yadav M, Joshi JM, Desai D, Moghe S. Active pre-treatment purepulmonary parenchymal sarcoidosis with raised serum angiotensin converting enzyme level: characteristics on PET with glucose metabolism and cell proliferation tracers and HRCT. Eur J Nucl Med Mol Imaging. 2011;38(8):1584–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Rayamajhi SJ, Mittal BR, Maturu VN, Agarwal R, Bal A, Dey P, Shukla J, Gupta D. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med. 2016;30(3):207–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Koo HJ, Kim MY, Shin SY, Shin S, Kim SS, Lee SW, Choi CM. Evaluation of mediastinal lymph nodes in sarcoidosis, sarcoid reaction, and malignant lymph nodes using CT and FDG-PET/CT. Medicine (Baltimore). 2015;94(27):e1095.CrossRefGoogle Scholar
  24. 24.
    Iwai K, Tachibana Y, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.PubMedGoogle Scholar
  25. 25.
    Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167–72.PubMedGoogle Scholar
  26. 26.
    Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F- fluorodeoxyglucosepositron emission tomography: an autopsy case. Circulation. 2010;122:535–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Hiraga H, Hiroe M, Iwai K, et al. Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases. Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23–4. in Japanese.Google Scholar
  29. 29.
    Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89–102.Google Scholar
  30. 30.
    Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55:99–106.CrossRefPubMedGoogle Scholar
  31. 31.
    Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Birnie D. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801–10.CrossRefPubMedGoogle Scholar
  35. 35.
    Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–36.CrossRefPubMedGoogle Scholar
  36. 36.
    Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F] fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol. 2002;4:232–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand. 1988;724:1–56.CrossRefGoogle Scholar
  39. 39.
    Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2015;23:244–52.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A doseresponse study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7:531–3.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, Ito N, Ohira H, Ikedo D, Tamaki N, Nishimura M. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26(15):1538–43.CrossRefPubMedGoogle Scholar
  42. 42.
    Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Baba K, Ishibashi M, Hayabuchi N, Narula J, Imaizumi T. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3(12):1219–28.CrossRefPubMedGoogle Scholar
  43. 43.
    Norikane T, Yamamoto Y, Maeda Y, Noma T, Dobashi H, Nishiyama Y. Comparative evaluation of (18)F-FLT and (18)F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res. 2017;7(1):69.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933–41.CrossRefPubMedGoogle Scholar
  45. 45.
    Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res. 2016;6(1):52.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T, Pizarro C, Skowasch D, Thomas L, Schlesinger-Irsch U, Thomas D, Bundschuh RA, Bauer WR, Gärtner FC. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807–14.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Grozdic Milojevic I, Sobic-Saranovic D, Videnovic-Ivanov J, Saranovic D, Odalovic S, Artiko V. FDG PET/CT in bone sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(1):66–74.PubMedGoogle Scholar
  48. 48.
    Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med. 2014;39(2):e146–59.PubMedGoogle Scholar
  49. 49.
    Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32(1):47–59.CrossRefPubMedGoogle Scholar
  50. 50.
    Aide N, Allouache D, Ollivier Y, de Raucourt S, Switsers O, Bardet S. Early 2′-deoxy-2′-[18F]fluoro-D-glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol. 2009;11(4):224–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):143–9.PubMedGoogle Scholar
  52. 52.
    Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, Djuric-Stefanovic A, Masulovic D, Odalovic S, Ilic-Dudvarski A, Popevic S, Pavlovic S, Obradovic V. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Maturu VN, Rayamajhi SJ, Agarwal R, Aggarwal AN, Gupta D, Mittal BR. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(4):372–80.PubMedGoogle Scholar
  55. 55.
    Tirpude S, Basu S, Joshi JM. FDG-PET scan in management of pulmonary sarcoidosis. J Assoc Physicians India. 2013;61(4):276.PubMedGoogle Scholar
  56. 56.
    Basu S, Asopa RV, Baghel NS. Early documentation of therapeutic response at 6 weeks following corticosteroid therapy in extensive sarcoidosis: promise of FDG-PET. Clin Nucl Med. 2009;34(10):689–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ashwini Kalshetty
    • 1
    • 2
  • Pradeep Thapa
    • 1
  • Sandip Basu
    • 1
    • 2
  1. 1.Radiation Medicine Centre, Bhabha Atomic Research CentreTata Memorial Centre AnnexeMumbaiIndia
  2. 2.Homi Bhabha National InstituteMumbaiIndia

Personalised recommendations